

**NUMIRA BIOSCIENCES ANNOUNCES PRESENTATION
AT ORTHOPAEDIC RESEARCH SOCIETY (ORS) 2012 ANNUAL MEETING**

Christopher P. Jerome, PhD to speak as panelist on Translational Animal Models in Orthopaedic Research

SALT LAKE CITY, Utah, January 17, 2012 – Numira Biosciences, a specialty contract research organization and leader in high resolution 3D imaging, and bone related models and services, today announced that Chris P. Jerome, PhD, Technical Director over Bone and Orthopedic Services, will speak on Bone Loss in Primates: A Preclinical Model for Osteoporosis, at a workshop on Translational Animal Models in Orthopedic Research, at the upcoming ORS 2012 Annual Meeting, on Sunday, February 5, 2012.

The workshop will discuss translational research, the transfer of basic science discoveries to human clinical problems, which relies heavily on comparative animal models of injury and dysfunction. However, in choosing an animal model, significant consideration must be given to species, model type (surgical, mechanical, or pharmacological vs. naturally occurring), and how closely those models mimic human disorders.

Dr. Jerome has worked in both academia and industry to develop approaches to assessing bone mass, loss, and formation in primates, which serve as a key preclinical model for studies of bone loss. Dr. Jerome will discuss the comparison between human and primate bone, and issues associated with using rodent models to study osteoporosis.

Dr. Jerome's bibliography includes over 50 peer-reviewed publications, with an emphasis on preclinical osteoporosis models and reproductive biology in primates. He also has strong expertise in technologies related to *in vivo* musculoskeletal research, including densitometry by DXA and pQCT, bone histology and histomorphometry/image analysis, and biomarkers.

The session is Sunday, February 5th, 2012, at 8:00am-9:30am, during Workshop 7 – Room 2024, at the Moscone West Convention Center, in San Francisco, California. The ORS Annual Meeting, February 4, through February 7, 2012, brings together over 3,500 international orthopaedic researchers for high quality interactions.

About Numira Biosciences

Numira is a rapidly growing provider of specialty contract research services to the pharmaceutical and medical device industries. Through the combination of several novel technologies and capabilities, we provide clients with an unmatched array of pre-clinical services for their research programs in inflammation, cardiovascular, oncology, pulmonary, renal, bone, and other areas of disease and/or therapy. Moreover, we are a recognized leader in high-resolution, quantitative imaging for drug and device development. Numira, a privately-held company, is venture-backed by vSpring Capital, the Tech Coast Angels, and Crocker Ventures. For more information on Numira, please visit www.numirabio.com.

Contact Info:

Mary Mathis

Senior Director, Marketing & Communications

Numira Biosciences Inc.

Tel: (801) 320-0682 Ext 325

mmathis@numirabio.com